MedTrace Logo

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT03580616 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2025-04-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS patients and assess preliminary indications of efficacy

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

L-Serine

L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.

Sponsors & Collaborators

  • Brain Chemistry Labs

    collaborator OTHER

  • Elijah W. Stommel

    lead OTHER

Principal Investigators

  • Elijah W Stommel, MD,PHD · Dartmouth-Htichcock Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-24
Primary Completion
2022-08-03
Completion
2022-12-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03580616 on ClinicalTrials.gov